美國聯合醫療 UTHR 深 滬
已收盤 07-25 16:00:00 美东时间
304.50
-1.910
-0.62%
華盛通- 最 高307.27
- 今 開306.80
- 成交量 31.09万股
- 最 低 302.1101
- 昨 收 306.41
- 總市值 137.35亿
- 52周最高 417.815
- 市盈率 靜 12.36
- 換手率 0.69%
- 52周最低 266.98
- 委 比 -12.92%
- 總股本 4510.66万
- 歷史最高 417.815
- 量 比 0.86
- 振 幅 1.68%
- 歷史最低 36.55
- 每 手 1
- 風險率 51.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多'HHS Finds Systemic Disregard for Sanctity of Life in Organ Transplant System; To Begin Reforming Organ Transplant System; HRSA's Independent Investigation Revealed Clear Negligence After Previous OPTN Board Claimed To Find No Major Concerns In Internal Review'
https://www.hhs.gov/press-room/hrsa-to-reform-organ-transplant-system.html#:~:text=It%20found%3A,serious%20ethical%20and%20legal%20questions.
07-22 01:17
美股大行评级 | 巴克莱上调 Robinhood目标价至102美元；瑞银下调京东目标价从58美元至50美元
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从25美元升至29美元；摩根士丹利：维持Legend Biotech"超配"评级，目标价从80美元升至81美元
07-11 09:04
JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $330
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $350 to $330.
07-08 23:41
美股大行评级 | 潜在涨幅83.3%！Robinhood获Keybanc升目标价至110美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners：维持再鼎医药(ZLAB)"跑赢大市"评级，目标价从73美元升至75美元</p> <p>• 美银证券：维持BioCryst Pharma(BCRX)"买入"评级，目标价从13美元升至15美元
07-02 09:54
Deep Dive Into United Therapeutics Stock: Analyst Perspectives (9 Ratings)
In the last three months, 9 analysts have published ratings on United Therapeut...
07-01 04:00
United Therapeutics And Intermountain Health Announced The World's First Patient Treated In A Clinical Study Of A Bioengineered External Liver Assist Product Called miroliverELAP
This study is the first human clinical trial of a manufactured organ alternative.The procedure was performed on a patient experiencing liver failure who was not eligible for a liver transplant. The procedure was
06-24 19:08
AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio?
11 large-cap stocks were worst performers last week: SJM, CHWY, IOT, UTHR, CVNA, APP, UAL, GRAB, EIX, LULU, MBLY. Analysts lower price forecasts.
06-15 21:08
美股大行评级 | 潜在涨幅超50%，数十家机构大幅上调甲骨文目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140203048973164544.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：上调Datavault AI(DVLT)评级至"买入"，目标价3美元</p> <p>• 蒙特利尔银行：维持DoubleVerify Holdings(DV)"跑赢大市"评级，目标价从25美元升至26
06-13 09:33
美股大行评级 | GitLab遭多家大行下调目标价！Stifel首予优步"买入"评级，目标价110美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139839943846023169.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Loop Capital：维持Dave & Buster's Enter(PLAY)"买入"评级，目标价从35美元升至46美元</p> <p>• Stifel：维持嘉年华(CCL)"买入"评级，目标价从31美元升至
06-12 09:46
Liquidia, United Therapeutics fall after mid-stage data for Insmed’s PAH asset
Insmed (NASDAQ:INSM) announced Tuesday that TPIP, its experimental therapy for pulmonary arterial hypertension, succeeded in a mid-stage trial, sending the shares of its rivals Liquidia (NASDAQ:LQDA) ...
06-10 19:58
